Could a brain chemical help repair Parkinson's?
NCT ID NCT06263010
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested a drug called allopregnanolone in 10 people with Parkinson's disease. The goal was to see if a larger study is possible and if the drug is safe. Participants received weekly infusions for 12 weeks, and researchers looked for signs of improvement on brain scans and symptom scales.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The University of Arizona Clinical & Translational Science Research Center
Tucson, Arizona, 85721, United States